Efficacy and Tolerability of Mirabegron Compared to Oxybutynin Chloride Immediate Release for Neurogenic Detrusor Overactivity in Persons With Chronic Spinal Cord Injury: A Randomized, Double-Blind, Controlled, Cross-Over Clinical Trial
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2018
Price : $35 *
At a glance
- Drugs Mirabegron (Primary) ; Oxybutynin (Primary)
- Indications Detrusor instability; Overactive bladder
- Focus Therapeutic Use
- Acronyms MOSET-SCI
- 08 Aug 2018 Planned initiation date changed from 8 Jan 2018 to 1 Sep 2018.
- 29 Nov 2017 Planned initiation date changed from 15 Sep 2017 to 8 Jan 2018.
- 16 Aug 2017 Planned initiation date changed from 5 Jul 2017 to 15 Sep 2017.